XML 48 R34.htm IDEA: XBRL DOCUMENT v3.25.2
Stock-Based Compensation Expense and Shareholders' Equity (Tables)
 12 Months Ended
Jul. 31, 2025
Stockholders' Equity and Stock-based Compensation [Abstract]  
Schedule of Stock-based Compensation Expense
Stock-based compensation expense related to stock options, Stock Awards, and the ESPP purchase rights is included in the consolidated statements of operations as follows (in thousands):
Fiscal years ended July 31,
202520242023
Stock-based compensation expense$161,678 $146,700 $143,566 
Net impact of deferred stock-based compensation(122)(240)(724)
Total stock-based compensation expense$161,556 $146,460 $142,842 
Stock-based compensation expense is included in the following categories:
Cost of subscription and support revenue$13,953 $13,425 $14,073 
Cost of license revenue136 186 463 
Cost of services revenue20,759 19,013 19,257 
Research and development41,760 40,213 39,865 
Sales and marketing43,270 34,590 29,925 
General and administrative41,678 39,033 39,259 
Total stock-based compensation expense161,556 146,460 142,842 
Tax benefit from stock-based compensation62,429 37,670 22,566 
Total stock-based compensation, net of tax effect$99,127 $108,790 $120,276 
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
Total unrecognized stock-based compensation expense related to the Company’s stock options, Stock Awards, and ESPP purchase rights as of July 31, 2025 is as follows:
Unrecognized Expense
(in thousands)		Weighted Average Expected Recognition Period
(in years)
Stock awards$274,666 2.0
ESPP purchase rights3,814 0.4
Total unrecognized stock-based compensation expense$278,480 
Schedule of Share-based Compensation, Restricted Stock Units Award Activity
A summary of the Company’s Stock Awards activity under the Company’s equity incentive plans is as follows:
Stock Awards Outstanding
Number of Stock AwardsWeighted Average Grant Date Fair Value
 Aggregate Intrinsic Value(1)
(in thousands)
Balance as of July 31, 20222,785,353 $110.47 $216,478 
Granted2,287,778 $66.36 
Released(1,391,162)$100.92 $97,324 
Canceled(267,263)$99.31 
Balance as of July 31, 20233,414,706 $85.68 $289,635 
Granted1,639,400 $93.63 
Released(1,569,451)$91.48 $168,144 
Canceled(282,589)$89.22 
Balance as of July 31, 20243,202,066 $86.60 $480,534 
Granted1,099,795 $179.92 
Released(1,473,839)$99.72 $284,544 
Canceled(155,165)$95.42 
Balance as of July 31, 20252,672,857 $117.25 $604,654 
Expected to vest as of July 31, 20252,672,857 $117.25 $604,654 
(1)Aggregate intrinsic value at each period end represents the total market value of Stock Awards at the Company’s closing stock price of $226.22, $150.07, and $84.82 on July 31, 2025, 2024, and 2023, respectively. Aggregate intrinsic value for released Stock Awards represents the total market value of released Stock Awards at date of release.
Schedule of Share-based Compensation, Stock options, Activity
A summary of stock option activity under the Company’s equity incentive plans is as follows:
 Number of Stock Options Outstanding Weighted Average Exercise PriceWeighted Average Remaining Contractual Life
(in years)
 Aggregate Intrinsic Value(1)
(in thousands)
Balance as of July 31, 202275,706 $61.93 8.7$1,196 
Granted121,168 $66.76 
Exercised(6,582)$34.60 $255 
Canceled(2,720)$69.60 
Balance as of July 31, 2023187,572 $65.90 8.8$3,549 
Granted— $— 
Exercised(15,517)$67.98 $1,061 
Canceled(5,217)$68.39 
Balance as of July 31, 2024166,838 7.9$14,088 
Granted— $— 
Exercised(56,880)$68.60 $6,982 
Canceled— $— 
Balance as of July 31, 2025109,958 6.8$17,828 
Vested and expected to vest as of July 31 2025109,958 $64.09 6.8$17,828 
Exercisable as of July 31, 2025109,958 $64.09 6.8$17,828 
(1)Aggregate intrinsic value at each fiscal year end represents the difference between the Company’s closing stock price of $226.22, $150.07, and $84.82 on July 31, 2025, 2024, and 2023, respectively, and the exercise price of outstanding stock options. Aggregate intrinsic value for exercised options represents the difference between the Company’s stock price at date of exercise and the exercise price.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
Fiscal years ended July 31,
20252024
Performance period
September 11, 2024 to September 11, 2027
September 13, 2023 to September 13, 2026
3-year historical volatility
36.0%35.0%
3-year risk free rate
3.4%4.5%
The fair value of the stock options is estimated at the grant date using the Black-Scholes option-pricing model, which included the following assumptions:
Fiscal years ended July 31,
202520242023
Expected term (in years)
*
*
6.0
Risk-free interest rate**
2.9% - 4.2%
Expected volatility**
32.1% - 33.1%
Expected dividend yield**—%
*No options were granted during fiscal years ended July 31, 2025, and 2024, respectively.
The Company estimated the fair value of the ESPP purchase rights using the Black-Scholes option pricing model with the following assumptions:
Fiscal year ended July 31,
202520242023
Expected term (in years)0.5
*
*
Risk-free interest rate4.3%**
Expected volatility42.1%**
Expected dividend yield—%**
*The ESPP was approved by stockholders in December 2024. Therefore, there were no ESPP purchase rights during the fiscal years ended July 31, 2024, and 2023, respectively.
Common Stock Reserved for Issuance As of July 31, 2025 and 2024, the Company had reserved shares of common stock for future issuance as follows:
July 31, 2025July 31, 2024
Exercise of stock options to purchase common stock109,958 166,838 
Vesting of stock awards2,672,857 3,202,066 
Shares available under stock plans4,505,472 5,450,102 
Shares available for ESPP
3,000,000 — 
Total common stock reserved for issuance10,288,287 8,819,006